ADC Screening in a Large Organoid Panel Reveals the Importance of Functional Assays for Predicting Tumor Response

Marten Hornsveld, Cinthya Del Angel Zuvirie, Peter van Schaik, Hester Bange, Xena van den Haak, Lama Alhaj Hasan, Steven Ly, Lenno Krenning, Ludovic Bourre, Marrit Putker

Antibody-drug conjugates (ADCs) are a cutting-edge approach in targeted cancer therapy, combining the specificity of monoclonal antibodies with the cytotoxic effects of chemotherapeutic agents.

In vitro efficacy testing is a critical step in ADC development and requires models that exhibit physiological human target-protein expression, growth factor signaling and DNA damage responses to allow for accurate predictions of efficacy. This study highlights the value of performing functional assays for preclinical ADC development.

Download this Poster to Discover:

• An organoid screening platform for ADC functional testing.
• How the combination of organoids with high content imaging can provide further insights into the ADC target engagement and mechanism of action.

Download the Poster Now!